TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06384352: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06384352 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06384352 Rescue Dossier →